Ahpra registration PHY0002298174
How these guides are written and reviewed →
The heart has two pumping chambers. In Uhl's anomaly the muscle of the right one — the side that sends blood to the lungs — never develops properly, so instead of a thick muscular wall there is a thin, almost transparent sheet. The old descriptions called it a parchment right ventricle, which is exactly what it looks like. A chamber like that cannot generate much force, so blood backs up behind it: into the liver, the abdomen and the legs. It is extremely rare — a few hundred cases have ever been described — and that rarity shapes everything about it, including how little firm evidence exists to guide treatment.
Definition
Uhl's anomaly is a congenital condition in which the muscular wall of the right ventricle is almost entirely absent. The inner and outer linings of the heart lie directly against one another with virtually no muscle in between.1,2
It was described in 1952 in an eight-month-old infant, and the original account of near-total absence of right ventricular myocardium remains the definition.1 It is present from birth rather than acquired, and it does not run in families in the way an inherited cardiomyopathy does.2
Fewer than a few hundred cases appear in the world literature. There are no trials, no guidelines specific to it, and no registries — the evidence is case reports and small series, which is worth stating plainly because it explains why management is reasoned from general heart failure principles rather than from anything specific.2,5
Pathophysiology
What is missing
During normal development the right ventricular wall thickens into working muscle. In Uhl's anomaly that process fails, and the surviving wall is a thin layer of fibrous and fatty tissue. The chamber often dilates because a thin wall stretches under pressure.1,2
Why that causes symptoms
A right ventricle that cannot contract effectively fails to move blood forward into the lungs. Two consequences follow. Less blood reaches the left side of the heart, so cardiac output falls and exertion becomes difficult. And pressure rises behind the failing chamber, producing the congestion of right heart failure — a swollen liver, fluid in the abdomen, swollen legs and raised neck veins.5
Rhythm disturbance
A dilated, scarred right ventricle is arrhythmogenic. Atrial and ventricular arrhythmias are described, and are part of why these patients are followed by an electrophysiologist as well as a heart failure team.2,7
How it differs from ARVC
This distinction is the most clinically consequential thing on the page, because the two conditions look superficially similar and are managed differently.2,3,4
- Uhl's anomaly is congenital and non-familial. The muscle never formed. It presents in infancy or childhood with heart failure, and the whole right ventricular wall is affected uniformly.1,2
- Arrhythmogenic right ventricular cardiomyopathy (ARVC) is inherited and progressive. Muscle that formed normally is progressively replaced by fat and scar, usually presenting in adolescence or adult life with arrhythmia rather than heart failure, and typically patchy rather than uniform.3,4
The practical difference is that ARVC carries a familial risk requiring cascade screening of relatives and has defined diagnostic criteria; Uhl's anomaly has neither.2,3,4 A diagnosis of one should not be treated as the other, and where the distinction is uncertain it is resolved in a specialist centre.2
Symptoms
Most cases present in infancy or early childhood; a minority are recognised in adult life with milder disease.2
- Breathlessness on exertion, and in infants poor feeding and failure to gain weight.2,5
- Swelling — of the abdomen, the liver and the legs, from congestion behind the failing ventricle.5
- Fatigue out of proportion to activity.
- Palpitations, or fainting, where arrhythmia is present.7
- Cyanosis — a bluish tinge — in some cases, where blood crosses from the right side of the heart to the left through a defect.2
Diagnosis
- Echocardiography, which shows a dilated, thin-walled, poorly contracting right ventricle.2
- Cardiac MRI, now the key investigation — it shows the absence of myocardium directly, and distinguishes it from the patchy fatty replacement of ARVC.2,3
- ECG and rhythm monitoring, both for arrhythmia and because the ECG changes overlap with ARVC.3,7
- Assessment against the ARVC Task Force criteria, which is how the alternative diagnosis is formally excluded.3
- Family history and, where ARVC remains possible, genetic testing — negative results support Uhl's anomaly, since it is not an inherited condition.2,4
Management
There is no treatment that replaces the missing muscle. Care is extrapolated from heart failure and congenital heart disease practice, and is highly individual.5,8
- Heart failure medication to reduce congestion and support the circulation — diuretics for fluid, and the standard heart failure agents where tolerated, recognising that the evidence base is for left ventricular failure.5
- Rhythm management, including antiarrhythmic drugs or a defibrillator where the arrhythmia risk warrants it.7
- Surgery in selected cases. Operations that reduce the work asked of the right ventricle — including the one-and-a-half ventricle repair and Fontan-type procedures — have been used, decided case by case in a congenital cardiac surgical centre.8
- Transplantation, which is the definitive option in severe disease.5,8
- Care in an adult congenital heart disease service for those reaching adulthood, rather than a general cardiology clinic.8
Outlook
Honesty is more useful here than optimism. Presentation in infancy with severe right ventricular failure carries a poor prognosis, and many of the published cases died young or required transplantation.1,2 Patients who reach adolescence or adulthood are described — sometimes with surprisingly preserved function — and modern heart failure care and surgery have changed what is possible.2,8
Because the literature is case reports, any figure quoted for survival is unreliable, and reported series are weighted towards the sickest and the most unusual. An individual outlook comes from the treating team, not from published rates.2
Living with it
The practical experience is that of chronic right heart failure: limited exercise tolerance, fluid that fluctuates, and a treatment routine that has to be kept up. Daily weights and an agreed plan for what to do when weight rises are the ordinary tools, and they apply here as in any heart failure.5
Because the condition is so rare, families are often better informed about it than the clinicians they meet. A written summary of the diagnosis, the imaging findings, any surgery and current medication is genuinely valuable to carry — more so than in a common condition.
Role of the physiotherapist
We do not treat the anomaly, and no physiotherapy alters the structure of the heart. The role is in function, and it is real but bounded:
- Exercise assessment and prescription within cardiology limits. Exercise-based rehabilitation improves exercise capacity and quality of life in heart failure, and there is no reason to think a person with right ventricular failure is excluded from that benefit — but the evidence comes from left ventricular failure populations and is extrapolated.6
- Working to a written cardiology plan. In a condition where arrhythmia and low output coexist, the intensity ceiling is a cardiology decision. We ask for it in writing, along with any device settings.7,9
- Pacing and energy conservation, which for many people matters more day to day than training does — organising activity so that the useful things in a day are possible.
- Breathlessness management, where congestion or deconditioning contributes.5
- Supporting monitoring — weights, symptoms and an escalation plan — alongside the heart failure service rather than in place of it.5
We are not the primary service for this condition, and we would not accept a referral without a current cardiology plan. Where we help is making the capacity that exists usable.
- Cardiorespiratory Rehabilitation — graded, supervised exercise within a written cardiology ceiling
- Physiotherapy Assessment — a functional baseline, and a plan built around what your day actually requires
- Functional Capacity Assessments — objective capacity documentation where a support plan or a return to work needs it
No physiotherapy changes the structure of the heart, and we are not the primary service here — we would not take a referral without a current cardiology plan. What we can do is make the capacity that exists usable: graded exercise within a written intensity ceiling, breathlessness management, and pacing so the useful parts of a day are possible.
Part 1 · References
- Uhl HS. A previously undescribed congenital malformation of the heart: almost total absence of the myocardium of the right ventricle. Bull Johns Hopkins Hosp 1952;91(3):197–209.
- Gerlis LM, Schmidt-Ott SC, Ho SY, Anderson RH. Dysplastic conditions of the right ventricular myocardium: Uhl's anomaly vs arrhythmogenic right ventricular dysplasia. Br Heart J 1993;69(2):142–150.
- Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force criteria. Circulation 2010;121(13):1533–1541.
- Corrado D, Link MS, Calkins H. Arrhythmogenic right ventricular cardiomyopathy. N Engl J Med 2017;376(1):61–72.
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42(36):3599–3726.
- Long L, Mordi IR, Bridges C, et al. Exercise-based cardiac rehabilitation for adults with heart failure. Cochrane Database Syst Rev 2019;1:CD003331.
- Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2022;43(40):3997–4126.
- Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J 2021;42(6):563–645.
- Pelliccia A, Sharma S, Gati S, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J 2021;42(1):17–96.
Clinical evidence
Part 1 covers the same condition without the technical detail. What follows is the evidence base behind it, written for clinicians — the literature, the reasoning and the gaps.
For clinicians: this summary supports clinical reasoning and is not a protocol. Check current guidelines and local policy before applying it, and read it alongside the key references and guidelines directory.
The evidence base is case reports, and that is the finding
Uhl's anomaly has no randomised evidence, no guideline of its own and no registry. The literature comprises the 1952 index description and subsequent case reports and small pathological series.1,2 Any statement about optimal management is therefore inference from congenital heart disease and heart failure practice, and should be presented as such — including to families, who are frequently searching for evidence that does not exist.5,8
Distinguishing it from ARVC is the substantive diagnostic question
Gerlis and colleagues set out the pathological separation: uniform, congenital, near-total absence of right ventricular myocardium in Uhl's anomaly, against progressive patchy fibrofatty replacement of previously normal myocardium in ARVC.2 The distinction carries three practical consequences — ARVC has validated Task Force diagnostic criteria and Uhl's does not; ARVC is heritable and mandates cascade family screening, while Uhl's is sporadic; and ARVC management is dominated by sudden-death risk stratification, whereas Uhl's is dominated by right ventricular failure.2,3,4
Cardiac MRI is the discriminating investigation, demonstrating absent myocardium rather than fibrofatty infiltration.2,3 Where the two cannot be separated confidently, the conservative course is to manage the arrhythmia risk as for ARVC while investigating further, since the consequence of under-treating ARVC is the more serious error.4,7
Management is extrapolated, and the extrapolation has a known weakness
Contemporary heart failure therapy is built on trials in left ventricular systolic dysfunction; isolated right ventricular failure was largely excluded from them, and neither ESC heart failure guidance nor adult congenital heart disease guidance can offer more than pragmatic recommendation here.5,8 Surgical strategies reported in Uhl's anomaly — one-and-a-half ventricle repair, Fontan-type palliation, transplantation — are individual decisions taken in congenital surgical centres, with case-level rather than comparative evidence.8
Exercise: benefit is plausible, the evidence is borrowed
The Cochrane review of exercise-based cardiac rehabilitation in heart failure found improved quality of life and reduced heart-failure hospitalisation, drawn overwhelmingly from left ventricular systolic dysfunction cohorts.6 ESC sports cardiology guidance addresses congenital and arrhythmogenic conditions with an emphasis on individualised assessment and, in significant right ventricular disease, avoidance of high-intensity endurance loading.9
The practical position for a physiotherapy service is that exercise should be offered, prescribed conservatively, and governed by a written cardiology ceiling — with the additional caution that right ventricular loading is intensity-dependent and that arrhythmia and low output can coexist.7,9
What we do not know
- Natural history. Reported cases are weighted towards the severe and the unusual, so survival figures are not generalisable and should not be quoted to families as though they were.1,2
- Whether standard heart failure pharmacotherapy benefits isolated right ventricular failure of this kind. Unstudied.5
- Which surgical strategy suits which anatomy, and at what age.8
- Arrhythmic risk stratification. ARVC risk tools are not validated in Uhl's anomaly and cannot simply be applied.4,7
- Safe exercise dose, where all recommendations are extrapolated and none tested.6,9
References for the clinical evidence summary
- Uhl HS. A previously undescribed congenital malformation of the heart: almost total absence of the myocardium of the right ventricle. Bull Johns Hopkins Hosp 1952;91(3):197–209.
- Gerlis LM, Schmidt-Ott SC, Ho SY, Anderson RH. Dysplastic conditions of the right ventricular myocardium: Uhl's anomaly vs arrhythmogenic right ventricular dysplasia. Br Heart J 1993;69(2):142–150.
- Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force criteria. Circulation 2010;121(13):1533–1541.
- Corrado D, Link MS, Calkins H. Arrhythmogenic right ventricular cardiomyopathy. N Engl J Med 2017;376(1):61–72.
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42(36):3599–3726.
- Long L, Mordi IR, Bridges C, et al. Exercise-based cardiac rehabilitation for adults with heart failure. Cochrane Database Syst Rev 2019;1:CD003331.
- Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2022;43(40):3997–4126.
- Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J 2021;42(6):563–645.
- Pelliccia A, Sharma S, Gati S, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J 2021;42(1):17–96.
Corrections: If something on this page is wrong, out of date or unclear, we want to know. Email reception@inspireclinic.au with the page name and what you believe is incorrect. Substantive corrections are made promptly, and the guide’s version and last-updated date are changed to reflect it.